VOT Is Struggling In 2026, Consider Core Mid-Cap Growth ETFs

This is less about one ETF underperforming and more about the market rewarding factor purity over blended exposure. If the market continues to favor higher-beta mid-cap cyclicals, vehicles with more industrial and financial sensitivity should keep widening the gap versus growth-heavy mid-cap wrappers; the second-order winner is likely the “boring” mid-cap value basket that picks up the rotation without paying up for duration-like earnings streams.

The valuation setup leaves little room for multiple expansion because the fund is already priced like a high-quality growth compounder, but its earnings mix is not clean enough to deserve that premium in a slowing-disinflation regime. That makes the downside asymmetric over the next 1-3 months: even a neutral market can still produce relative underperformance if the crowd keeps chasing cheaper mid-cap exposure elsewhere. The biggest loser is likely any adjacent product offering similar upper-mid-cap tech and health care exposure, since relative performance comparisons will get harsher as institutions benchmark more tightly to core mid-cap peers.

The contrarian angle is that this underperformance can persist until earnings revisions stabilize in the upper-mid-cap growth cohort; if rates fall faster than expected, the higher-duration components of the portfolio could rebound sharply and compress the relative valuation gap. But absent a clear catalyst from the macro side, the current setup looks more like a structural hold than a tactical buy, because the fund is paying a growth multiple for a mix that is not delivering growth-style surprise. The key watch item is whether industrial leadership broadens again; if it does, this product remains a relative laggard rather than a turnaround candidate.